4D Molecular Therapeutics, Inc. (FDMT) Stock Forecast
FDMT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 12 analysts
- Price target
- $28.09 average of analyst targets
- Upside to target
- +131.4% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-1.03
- 52-week range
- $7.19 – $16.76
FDMT analyst ratings
12 analystsNumber of analysts at each rating.
FDMT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FDMT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.05 | −$1.10 | −$0.99 | −$1.01 | −4.0% | 11 |
| Current fiscal year (2026) | −$4.15 | −$4.30 | −$4.00 | −$2.42 | −71.5% | 11 |
| Next fiscal year (2027) | −$4.09 | −$4.94 | −$3.38 | −$4.15 | +1.4% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FDMT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.1M | $0 | $5.6M | +3,341.8% | 8 |
| Current fiscal year (2026) | $13.3M | $6.8M | $22.5M | −84.4% | 10 |
| Next fiscal year (2027) | $20.6M | $0 | $43.6M | +55.6% | 8 |
FDMT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FDMT revenue: reported and forecast
FDMT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.01 | −$1.04 | −$1.04 | −$1.05 | −$1.05 | +3.6% | 1 up · 1 down |
| Current fiscal year (2026) | −$3.93 | −$4.14 | −$4.14 | −$4.15 | −$4.15 | +5.7% | 1 up · 0 down |
| Next fiscal year (2027) | −$3.73 | −$4.09 | −$4.09 | −$4.09 | −$4.09 | +9.9% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FDMT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FDMT beat in 6 of 12.
What analysts expect from FDMT
12 analysts cover 4D Molecular Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $28.09, 131.4% above the latest close of $12.14. Analysts expect earnings of −$4.15 per share for 2026, −71.5% from a year earlier. For 2027 the average estimate is −$4.09 per share on revenue of $20.6 million. 4D Molecular Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: FDMT income statement, FDMT key metrics, FDMT chart. See the FDMT stock overview for the latest quote and news.
FDMT forecast FAQ
What is 4D Molecular Therapeutics's price target?
The average analyst price target for 4D Molecular Therapeutics is $28.09, 131.4% above the latest close of $12.14.
Is 4D Molecular Therapeutics a buy, hold or sell?
Of 12 analysts covering 4D Molecular Therapeutics, 9 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is 4D Molecular Therapeutics's EPS forecast?
Analysts forecast −$4.15 per share for 2026 (range −$4.30 to −$4.00); for 2027 the estimate is −$4.09.
What is 4D Molecular Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $13.3 million, growth of −84.4%; for 2027 it is $20.6 million.
When does 4D Molecular Therapeutics report earnings?
4D Molecular Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-1.03.
Does 4D Molecular Therapeutics usually beat earnings estimates?
4D Molecular Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.